J Pediatr Ophthalmol Strabismus. 2020 Sep 1;57(5):301-304. doi: 10.3928/01913913-20200803-01.
To evaluate the efficacy and tolerability of cyclopentolate 1% administered as a spray in pediatric patients between 3 and 6 years old.
In this prospective, randomized, parallel group study, healthy volunteers were randomly assigned to receive cyclopentolate 1% as a single drop or a single puff into closed eyes.
There were 61 patients included in the study; 31 received cyclopentolate 1% as drops and 30 received cyclopentolate 1% as spray. The mean age at presentation was 4.5 ± 1.07 years (range: 3 to 6 years) and 4.2 ± 1.06 years (range: 3 to 6 years) in the drops and spray groups, respectively. The distress level was significantly lower at the time of receiving cyclopentolate as a spray (P < .0001), with the exception of patients aged 6 years. There were no significant differences in pupil diameter between the two groups (P = .51), whereas 5 of 30 patients (16.6%) with dark irises who received cyclopentolate spray did not have adequate cycloplegia to allow for accurate refraction.
Cycloplegia achieved with cyclopentolate 1% administered as a spray may be an option in uncooperative children because it is less distressing compared to cyclopentolate 1% drops. However, physicians should be aware that cycloplegia obtained is only partially effective in children with dark irises. [J Pediatr Ophthalmol Strabismus. 2020;57(5):301-304.].
评估 3 至 6 岁儿童使用 1%环戊通作为喷雾剂的疗效和耐受性。
在这项前瞻性、随机、平行组研究中，将健康志愿者随机分为单滴或单喷环戊通 1%入闭眼睛。
共有 61 例患者纳入研究；31 例患者接受 1%环戊通滴剂，30 例患者接受 1%环戊通喷雾剂。滴注组和喷雾组的平均年龄分别为 4.5±1.07 岁（范围：3 至 6 岁）和 4.2±1.06 岁（范围：3 至 6 岁）。在使用喷雾时，患者的不适感明显降低（P<.0001），除了 6 岁的患者。两组瞳孔直径无显著差异（P=0.51），然而，接受环戊通喷雾的 30 例虹膜较深的患者中，有 5 例（16.6%）没有足够的睫状肌麻痹来进行准确的屈光检查。
与 1%环戊通滴剂相比，使用 1%环戊通作为喷雾剂可能是不合作儿童睫状肌麻痹的一种选择，因为它的不适感较低。然而，医生应该意识到，在虹膜较深的儿童中，获得的睫状肌麻痹效果只有部分有效。
